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Introduction
What are Lattice Energy and Sublimation Enthalpy, and Why are They Interchangeable in Describing The Packing Energy of Crystals?
The packing energy of a crystal is an important quantity that can impact various commercial processes, 1 particularly in pharmaceutical development where it plays a crucial role in solubility, 2,3 stability, 4 and processability. 5 These publications highlight the importance of disrupting the solid-state lattice energy to improve solubility, the link between solid-state interactions and chemical and physical stability, as well as the application of cohesive energy density to predict mechanical properties and processability. Lattice energy (E latt ) is a direct sum of the solid-state interactions and is usually a calculated value that represents the packing energy. It is the amount of energy needed to separate molecules in a perfect crystal lattice to individual molecules in the gas phase (disregarding thermal and vibrational contributions). Lattice energy can be calculated from the sum of all the interactions between the central molecule in a crystal and the surrounding molecules [6] [7] [8] [9] [10] ; these interactions include van der Waal's, hydrogen bonding and electrostatic forces. The equation that describes the calculation of the lattice energy is as follows 10, 11 :
where the lattice energy (E latt ) is a summation of all atom-atom interaction pairs (V kij ), N is the total number of molecules surrounding a designated central molecule containing n atoms, and n' atoms in each of the surrounding molecules. Lattice energy calculations have been extensively validated by comparing these intermolecular potentials against known crystal structures and experimental sublimation enthalpies. 6 Sublimation enthalpy (DH sub ) has also been used to represent the packing energy and is the amount of energy required to convert a crystal from the solid state to the gas state and is determined experimentally by measuring the vapor pressure of the solid phase as a function of temperature. 1, 11 Like E latt , DH sub represents the strength of the intermolecular interactions in a crystal and its physical stability. Therefore, both DH sub and E latt can and are used interchangeably to describe the packing energy of a crystal. 11 Using calculated lattice energy instead of sublimation enthalpy to describe the solid phase has several advantages.
The experimental determination of the DH sub of pharmaceutical crystals is challenging, as they generally have low vapor pressures, which requires an increase in temperature for such measurements, often inducing chemical instability in the molecule. 12 There are experimental methods that can overcome these issues, [13] [14] [15] [16] but it would be challenging and time-consuming to generate a data set of sufficient quantity, diversity, and quality for use in a quantitative structure-property relationship (QSPR) model. In addition, we are able to quantify the atom-atom and group contributions to lattice energy along specific crystallographic directions, thus allowing the optimization of physical properties during early-stage discovery. 6 To calculate E latt , knowledge of crystal structure must first be determined experimentally or predicted through crystal structure prediction methodologies as described in the literature. [17] [18] [19] [20] [21] [22] An Outline of QSPR Approaches
The intrinsic structural properties of molecules impact critical drug product performance attributes such as biopharmaceutical and mechanical properties. [23] [24] [25] [26] [27] Creating a drug product with the desired bioavailability and solid form properties has been a challenge in pharmaceutical development for many years. In a recent study comparing the solubility differences between pairs of molecules with minor structural modifications, it was shown that solubility differences are strongly influenced by packing energy differences. 6 The technique of structural modification to reduce packing energy as a means of improving solubility has also been explored. 12 Solubility models have grown in importance, reflecting the increasing number of poorly soluble drug candidates emerging from drug discovery programs. [26] [27] [28] [29] [30] [31] [32] [33] [34] Because lattice energy is one of the components used for solubility prediction, an understanding of packing energy can help improve these predictions. 35 Computational and experimental approaches to determine the packing energy could be applied at the early stage of drug development, but a quicker solution would be a QSPR model. These types of models have been applied to other areas of interest to pharmaceutical development, [36] [37] [38] [39] [40] including bioactivity, 39 ADMET (absorption, distribution, metabolism, excretion and toxicity) 40 and melting point. 41, 42 These articles demonstrate the continued academic community and industrial interest in this area.
There have been numerous previous attempts to build QSPR models for sublimation enthalpy. While not exhaustive, Figure 1 provides a high-level timeline of various approaches to predicting the solid-state energies of organic crystals. This timeline outlines the evolution of DH sub prediction models using simple parameters 43, 44 to models that utilize more complex descriptors and include larger, more chemically diverse data sets. 1, 42, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Examples of the most recent models include a model incorporating machine learning algorithms and calculated Chemistry Development Kit descriptors, 35 a hybrid QSPR model combining HYBOT (Hydrogen Bond Thermodynamics) descriptors with experimental melting points 58 and a modified electrostatic potential model. 59 The wealth of accurate predictive models within specific data sets as described previously is remarkable; however, there is still a need for an enhanced predictive model tailored to complex, conformationally flexible drug molecules which are typical of those currently in development. These types of molecules differ from small organic molecules and less-complex drug molecules because of the greater size, flexibility, and multiple competing hydrogen bonding and p-p stacking arrangements. 24 The gap in the predictive model ecosystem was exemplified during the use of a highly accurate lattice energy model built on a chemically diverse data set of small molecules to predict the E latt of a small subset of drug-like molecules where the result was a noticeable drop in accuracy for higher lattice energies. 6 
Our Solution to Limited Data Sets for Drug Molecules to Enable the Building of Predictive Models
To build an accurate predictive model for the packing energies of drug molecules, 2 main elements are requiredda large data set of reliable packing energy values for drug molecules and quality molecular descriptors. While the availability of the latter is demonstrated in the previous section, unfortunately the former is not. To address this, we have constructed a large data set of in-house molecules where lattice energy values have been calculated from crystal structures. Our new model requires only 2-D molecular structures to predict the lattice energies of in-house drug molecules, which allows use of the model before crystal structures are determined. We also demonstrate proof-of-concept by showing the high correlation and interchangeability between 2 QSPR models built using calculated lattice energies and equivalent experimental sublimation enthalpies. Normally, drugs are chosen for their biological properties in early stage development, with solid form properties optimized for drug product performance in later stages. 24 This creates a gap between early-stage medicinal chemists and pharmaceutical scientists, which the following machine learning algorithm trained purely on drug compounds is intended to help bridge. This model is intended to be used by early discovery chemists to determine how changes to a molecule would affect the packing energy of a polymorph without needing to solve the crystal structure. One of the limitations of the model is that it predicts the likely lattice energy for a single polymorphic form and it does not reflect the relative stability of the polymorphs for a given molecule. The vast majority of companies will want to develop a crystalline form. Those needing to develop an amorphous form will ultimately need to understand the potential impact of an amorphous to crystalline transition and the tools here can help qualify this risk. Figure 2 summarizes the model building process from initial data curation to validation of the model on a test set and blind set. Table 1 describes the data sets that were used in building and testing the models described in Table 2 . Two models (models 1a 2015 were found by searching our in-house crystal structure databases using the Cambridge Structural Database tools (The vast majority (>99%) of the crystal structures were collected at room temperature). The training set included numerous different pairs of molecules with similar backbones and different functional groups. The systematic exploration of matched molecular pairs and their impact on crystallographic features, and the application of the methodology of this article to differentiating the energies of matched molecular pairs is the subject of ongoing research (J. Janowiak, unpublished data). We excluded molecules with the following criteria: R-factor greater than 5%, Z' greater than 1, charged groups (e.g., nitro groups, zwitterions, and hydrates), and disorder. The rationale for this was to generate a data set that would be less likely to contribute to random errors and bias in the final model. On occasion there were multiple crystal structures for the same molecule, the structure with the strongest lattice energy was retained for each molecule, resulting in a data set of one crystal structure per molecule. Based on the methodology described in the systematic exploration of parameters affecting lattice energy (R.L. Marchese Robinson et al, unpublished data), the following approach was used. The Materials Studio Forcite module 62 was used for geometry optimization and the COMPASS II 63 force field was used to calculate the lattice energies of the molecules. The lattice energy of the optimized structure was calculated using the summation method shown in Equation 1 where the interactions energies in the summation used parameterization from the COM-PASS II force field. COMPASS II was chosen over other methods such as DFT because it has proven to be a computationally inexpensive and accurate force field in other in-house projects. SMILES strings were then generated from each crystal structure in the data set. A data set of 61 in-house molecules from 2016 onward was also generated by following the same method as aforementioned, designated as the blind test set C.
Methods

Data Preparation
Model Building
Our in-house software that provides a standardized environment for building, comparing and sharing in silico models was used to build the models in Table 2 . Identical settings were used in building both proof-of-concept models 1a and 1b, where the data set of 134 small organic molecules was imported into the software, then MOE-2D descriptors 64, 65 were selected for model building after removing zero-variance descriptors and descriptors where the Pearson pairwise correlation coefficient was more than 0.85. The MMFF94X 66 force field was used to calculate geometric parameters such as ideal bond length and van der Waals radii. This force field was chosen because it is parameterized for a wide chemical space that includes drug-like compounds. Next, the data set was partitioned into training (80%) and test (20%) sets using a maximum dissimilarity method that populates the training and test sets based on maximum distance within a specified descriptor space, resulting in training and test sets that are representative of the original data set. The same parameters, training and test sets, were used to train both proof-of-concept models; the only difference was the prediction endpoint of DH sub for model 1a and E latt for model 1b. The next stage was selecting the model algorithm, for which the advanced machine learning algorithm, Cubist, 67,68 was chosen. The Cubist algorithm has been successfully applied in other studies 26, 40, 69, 70 and allows quick building of different iterations of the model and testing changes in tuning parameters, the addition of training molecules and descriptors. Cubist is a rule-based model where each rule is a conjunction of multivariate linear regression models. The method uses a sequence of rule-based models, called committees and each committee member predicts the target endpoint. The final prediction is the average of the individual model predictions which increases model accuracy. Prediction accuracy can also be improved by a nearest-neighbor correction, where the algorithm finds the n most similar training molecules (based on the calculated descriptors) and averages their predicted values to adjust the model prediction. The methodology automatically selects the optimum parameter settings for each model built. The tuning parameters were kept consistent for models 1a and 1b to enable a fair comparison of prediction accuracies and analysis of descriptors. With regard to the important descriptors used in the model, Cubist is able to select these automatically, thus reducing the likelihood of overfitting from the presence of noise descriptors. The algorithm is also able to rank descriptor importance by how frequently they are used in the final model. The risk of overfitting was also reduced by using k-fold cross-validation (k ¼ 50 for models 1a/1b and k ¼ 20 for model 2).
For model 2, 1545 in-house molecules were partitioned into training (90%) and test (10%) sets and a set of MOE-2D descriptors were selected after removing descriptors with zero variance and where the Pearson pairwise correlation coefficient was more than 0.70. These parameters were selected because they resulted in a more accurate prediction result of the test set in the preliminary models.
A variety of models were built using different tuning parameters, training and test set splits and descriptor sets (e.g., MOE-3D, DragonX 71 ). We chose the most accurate model by comparing the squared correlation coefficient (R 2 ) and root mean square error of the training and test sets of our in-house data set (test set B) and the blind set of in-house molecules from 2015 onward (blind set C).
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where the R 2 and root mean square error were similar for 2 models, the model with the lowest prediction residuals for compounds with Figure 5 . Scatter plots comparing the predicted values against the experimental sublimation enthalpy and calculated lattice energy of test set A using models 1a and 1b. Lattice energy and sublimation enthalpy data are given in kJ/mol to be consistent with the original data source. The points are colored according to the AtomPair similarity score of the nearest neighbour in the training set. stronger lattice energies was chosen. Two prediction confidence metrics were included in the final model, AtomPair, 72,73 a descriptor based on atom environments and 2D alignment methodology called PZIM. 74 Prediction confidence metrics are used when a model is applied to blind molecules and indicate the similarity of the blind molecule to molecules in the training set. Therefore, they are useful to evaluate the uncertainty in a model's prediction of a blind molecule. The metrics included provide the number of nearest neighbors found in the training set and the similarity score of the nearest neighbor. For both metrics, the similarity threshold was set to 0.7 (range between 0.1-1.0) and the atom distance used in PZIM was set to 5 (range between [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . A more accurate prediction would be expected for molecules with higher scores, and lower scores would indicate a less certain prediction.
Results and Discussion
A comparison of the molecular characteristics of the training and test sets of the proof-of-concept models 1a and 1b, our new model (model 2) and the data set from the recently published article by Salahinejad et al. 42 is shown in Figure 3 . These characteristics are defined in terms of molecular descriptors: conformational flexibility calculated using the nconf20 descriptor, 75 molecular weight, topological polar surface area, and van der Waal's surface area of pure hydrogen bond acceptors calculated using the MOE-2D descriptors. 64, 65 This comparison highlights the differences between small organic molecules and drug molecules currently in development. The distributions and medians of the molecular descriptors reflect the increased weight, size, conformational flexibility and hydrogen bonding potential of our data set. In particular, the combination of increased conformational flexibility and hydrogen bonding potential would alter the way molecules pack in the solid state. Models 1a and 1b provide supporting evidence that lattice energy and sublimation enthalpy can be used interchangeably to describe packing energy because the prediction accuracies of models trained on either endpoint are equally accurate (Figs. 4 and 5) . As such, a training data set of drug molecules with calculated lattice energies can be used successfully to build a QSPR model specific to drug molecules. Model 2 has an R 2 of 0.915 when applied to test set B (in-house test set of 154 molecules) and 0.795 for blind set C (separate in-house blind set of 61 drug molecules) ( Figs. 6 and 7) . This suggests that the model presented here is applicable to our chemical space and may be suitable for a wider range of drug molecules. The wider applicability of our model outside of our training set is indicated by the AtomPair similarity scores which include the number of nearest neighbors found in the training set and the similarity score of the nearest neighbors. Figure 5 shows that despite reasonable prediction accuracy, the AtomPair scores are both 0, indicating a low degree of similarity in our in-house data set from 2016 onward. This shows the need to build on our model with a cross-industry collaboration. Figures 8 and 9 provide a rough, qualitative comparison of the models and their training sets by categorizing the top 10 descriptors of each model (ranked by the machine learning algorithm) into broad categories. The descriptors were classed into categories according to their general description of the physical characteristics of molecules (for full details see Appendix 4) . There are minor differences between the ranking of descriptors for models 1a/1b and this is expected due to the differences in training endpoints. For all models, descriptors relating to size dominate and this is also observed when comparing to descriptors used in other models in the literature. 1, 32, 35, 53 Shape and polarity descriptors appear in the top 10 ranking for models 1a/1b, but not in model 2, where hydrogen bonding descriptors have a more important role. Polarisability descriptors are also more significant in models 1a/1b than model 2. This may reflect a relatively greater significance of hydrogen bonding for larger drug molecules, which would reduce the ranking of other descriptors related to size, shape, polarisability, or polarity. Hydrogen bonding descriptors are not as crucial in models 1a/1b, although these descriptors feature frequently in other published models. 1, 35, 42, 53, 58 Interestingly, rotational flexibility has a surprisingly minimal role compared to other descriptors across all models, suggesting that this characteristic is not as important as originally expected in determining the packing energies of larger molecules. The observations above could be useful in our vision of designing drug molecules with optimal physical properties.
The analysis of the models in terms of data set composition and descriptor importance show that when attempting to build a model tailored to drug molecules, using a training set of small organic molecules will be insufficient to achieve appropriate/required accuracy; therefore, a training set consisting of a significant weighting of drug molecules is necessary. This is due to the different weightings of descriptors that reflect the molecular characteristics and the different balance of intermolecular interactions that ultimately manifests itself in the crystal packing of drug molecules.
Sources of Error Overview
Despite satisfactory results, an understanding of prediction errors would inform future modeling endeavors as well as help us to understand the limitations of our current model. Errors can be attributed to several possible causesdforce field, descriptors, and data set composition. The COMPASS II force field was trained on 2 separate training sets. The first set included mostly smaller molecules with one functional group while the second set contained larger molecules with at least 2 functional groups which more closely resembled our chemical space. The authors compared the force field calculations for the 2 training subsets with quantum mechanics data and found a slight increase in errors for the larger molecules. 63 A possibly less significant source of error is the MOE-2D descriptors used in this work; these are calculated from a table of van der Waals radii and ideal bond lengths derived from the MMFF94X force field. The core parameterization of this force field treats over 20 chemical families that appear in drug compounds; however, the authors mention that many more combinations of functional groups would be required to optimally describe druglike compounds. 66 Another possible cause of prediction errors could be an inherent weakness of molecular descriptors which only take into account short-range packing between adjacent molecules and do not account for long-range packing effects. The contribution of long-range packing effects is usually not as significant as those arising from short-range effects 26 ; nonetheless this may be the cause of the underestimation seen for some molecules. In addition to neglecting long-range order, the relative scarcity of data points with very strong lattice energies (i.e., less than À70 kcal/mol) in the training set of model 2 could also explain the decline of prediction accuracy of blind set C at stronger packing energies (Fig. 6 ).
Conclusion
Our new QSPR model trained on calculated lattice energies can predict the lattice energies of in-house drug molecules based on the 2-D structure alone with acceptable accuracy. This new model tailored to our chemical space will allow us to evaluate likely changes in physical properties such as solubility in the early stages of drug discovery before a crystal structure is obtained. To prove that a packing energy model can be trained using calculated E latt values, we have built proof-of-concept models that demonstrate the interchangeability between calculated E latt and experimental DH sub values in model building. We have established that the molecular characteristics of drug molecules compared with small organic molecules are significantly different and as such, require a bespoke model specific to drug molecules to predict packing energies with a high degree of accuracy. Potential sources of prediction errors are addressed. Suggestions for future iterations of a packing energy QSPR model include obtaining quality DH sub measurements for drug molecules, using heat of fusion measurements or density functional theory methods to calculate the lattice energies of training sets. A cross-industry aim to enrich the training set with a greater quantity and diversity of molecules would also be valuable in improving the accuracy and range of applicability of our model. The application of big data and predictive sciences to streamline pharmaceutical development as exemplified by our model, and on a wider scale, with the Advanced Digital Design of Pharmaceutical Therapeutics (ADDoPT) program, 76 shows the growing momentum in this area. As part of the ADDoPT program, a cross-community effort involving the University of Leeds, Cambridge Crystallographic Data Centre, and the Hartree Center 77 has developed a model across a larger data set involving 50,000 crystal structures using a similar philosophy. This model will be published elsewhere and tested against crossindustry data sets such as the example described in this article. This publication will demonstrate the opportunity for crossindustry big data analytics applied to fundamental pharmaceutical development challenges. During the final preparation of this article, an elegant article describing the application of crystallographic information, computational chemistry and machine learning 78 showed the potential of fusing these components to predict material properties.
